SEMA3C was associated with poor prognosis of patients with THCA, PAAD, LUAD, KIRP, KIRC, HNSC, CESA, and AML, but favored survival for patients with UVM, MESO, and DLBC. Here, SEMA3C is linked to acute myeloid leukemia.